Introduction {#sec1_1}
============

Initially described after treatment with flutamide, responses to withdrawal of hormonal therapies in prostate cancer patients have been documented after cessation of other antiandrogens -- such as nilutamide, bicalutamide, or cyproterone acetate -- and of megestrol acetate, diethylstilbestrol or estramustine. In the Southwest Oncology Group Trial 9426, 21% of 210 patients had confirmed PSA decreases of ≤50% after treatment with nonsteroidal antiandrogens with a median progression-free survival of 3 months \[[@B1]\]. It has been proposed that withdrawal responses could result from mutations in the androgen receptor (AR). Transfection experiments revealed that AR point mutations in the hormone-binding domain allow activation by ligands other than dihydrotestosterone. Mutated AR from clinical samples was shown to be activated by progesterone, estradiol, adrenal androgens, hydrocortisone or hydroxyflutamide \[[@B2]\]. However, a prospective study failed to demonstrate a clear association between detectability of AR mutations and antiandrogen withdrawal responses \[[@B3]\].

An improvement in overall survival has been reported with abiraterone acetate (AA), a selective inhibitor of cytochrome P450c17 (CYP17), in castrate-resistant prostate cancer patients who have failed docetaxel chemotherapy \[[@B4]\]. The addition of low-dose corticoids to AA is mandatory in daily practice since the combination has been shown to minimize the syndrome of secondary mineralocorticoid excess related to CYP17 inhibition \[[@B5]\]. Here, we report the case of a patient who had a confirmed PSA decrease of ≤50% after stopping AA, mimicking a withdrawal syndrome.

Case Report {#sec1_2}
===========

A 60-year-old patient was diagnosed with a prostate adenocarcinoma (Gleason score 8, 4 + 4) with synchronous bone metastases in April 2007. He successively received an LHRH agonist, a combined androgen blockade with LHRH agonist and bicalutamide, without subsequent response to bicalutamide withdrawal, docetaxel (10 cycles), then mitoxantrone (3 cycles) and diethylstilbestrol. In April 2011, serum PSA increased to 77 ng/ml without bone pain. AA was started at the standard dose of 1,000 mg daily in combination with prednisone (5 mg twice daily). PSA slightly decreased to a nadir of 68 ng/ml one month after the start of treatment. In parallel, a metabolic partial response according to consensus criteria on 18-fluorodeoxyglucose positron emission tomography (PET) and choline PET (ΔSUVmax = −37%) was observed \[[@B6]\]. However, AA and prednisone were stopped in August 2011 because of back pain related to vertebral metastases and concomitant PSA progression (PSA 128 ng/ml). One month later, a confirmed PSA decrease to a nadir of 62 ng/ml occurred, defining a partial biological response according to standard criteria, with a concomitant improvement in back pain \[[@B7]\]. Three months after stopping AA, a biological and clinical progression occurred (**fig. [1](#F1){ref-type="fig"}**).

Discussion {#sec1_3}
==========

To the best of our knowledge, this is the first case ever reported of a withdrawal response with AA. Currently proposed mechanisms of resistance to AA include ligandless activation of AR by constitutively active variants lacking the ligand-binding domain, cross-talk with relative signaling pathways and/or activation of amplified or promiscuous AR by nonandrogenic ligands such as corticosterone or other steroids \[[@B8]\]. Following the latter hypothesis, the withdrawal response observed in the present case could be related rather to prednisone than to AA itself as it was stopped at the same time. Further reports are required to confirm such a phenomenon.
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